Literature DB >> 8980212

Should clinical trials with concurrent economic analyses be blinded?

N Freemantle1, M Drummond.   

Abstract

Mesh：

Year:  1997        PMID： 8980212

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  10 in total

1.  A randomised controlled trial of the effect of educational outreach by community pharmacists on prescribing in UK general practice.

Authors:  Nick Freemantle; Irwin Nazareth; Martin Eccles; John Wood; Andrew Haines
Journal:  Br J Gen Pract       Date:  2002-04       Impact factor: 5.386

2.  The problem of protocol driven costs in pharmacoeconomic analysis.

Authors:  D Coyle; K M Lee
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

3.  Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.

Authors:  D L Kendler; M R McClung; N Freemantle; M Lillestol; A H Moffett; J Borenstein; S Satram-Hoang; Y-C Yang; P Kaur; D Macarios; S Siddhanti
Journal:  Osteoporos Int       Date:  2010-09-09       Impact factor: 4.507

4.  Real-world trials to answer real-world questions.

Authors:  Nick Freemantle; Lawrence Blonde; Bjorn Bolinder; Robert A Gerber; F D Richard Hobbs; Luc Martinez; Stuart Ross
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma.

Authors:  M P Rutten-van Mölken; E K van Doorslaer; M D Till
Journal:  Pharmacoeconomics       Date:  1998-12       Impact factor: 4.981

6.  Decision-analytic valuation of clinical information systems: application to an alerting system for coronary angiography.

Authors:  D S Bell
Journal:  Proc AMIA Annu Fall Symp       Date:  1997

7.  Incremental cost-effectiveness ratio of alteplase in patients with acute myocardial infarction in the French setting.

Authors:  A Pelc; J Dardenne; J H Frelon; G Hanania
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

Review 8.  The importance of achieving additional drug benefits at a reasonable cost. A review of the fluoxetine years.

Authors:  N Freemantle; J Mason
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

9.  Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia.

Authors:  Lei Chen; Haya Ascher-Svanum; Anthony Lawson; Virginia L Stauffer; Allen Nyhuis; Virginia Haynes; Kory Schuh; Bruce J Kinon
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-14       Impact factor: 2.570

10.  Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.

Authors:  N Freemantle; L Meneghini; T Christensen; M L Wolden; J Jendle; R Ratner
Journal:  Diabet Med       Date:  2013-02       Impact factor: 4.359
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.